A transgenic platform for testing drugs intended for reversal of cardiac remodeling identifies a novel 11βHSD1 inhibitor rescuing hypertrophy independently of re-vascularization.

by Oren Gordon, Zhiheng He, Dan Gilon, Sabine Gruener, Sherrie Pietranico-Cole, Amit Oppenheim, Eli Keshet
Published 2014-01-01